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complexes and releases bound Cip/Kip
proteins. Agents acting “upstream” (such
as inhibitors of Ras, Raf, and PI3 kinas-
es) can prevent the induction of cyclin
D1, limit its stability, or interfere with its
assembly with Cdks, and these might
prove efficacious. The ultimate goal must
be to translate these important new
molecular insights into more effective
treatment of MCL; until then, we will con-
tinue to measure success as extended
survival and not cure.
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P R E V I E W S
The c-Jun protein is a component of
transcription factor AP-1 (Angel and
Karin, 1991), encoded by the c-jun gene
(using mouse gene terminology), the
cellular homolog of the retroviral v-jun
oncogene (Vogt, 2001). The discovery
fifteen years ago that c-Jun together
with c-Fos is a component of AP-1, a
transcription factor implicated in the
induction of gene transcription by phor-
bol ester tumor promoters (Angel et al.,
1987), generated a great deal of excite-
ment at the time. For once it suggested a
biochemical function for c-Jun being one
of the first sequence-specific transcrip-
tion factors found to be encoded by a
proto-oncogene. Even more importantly,
it suggested that the putative pro-onco-
genic function of c-Jun is due to its func-
tion at the receiving end of a signal
transduction pathway that mediates
gene induction by phorbol esters and
other tumor promoters. This discovery
also provided a molecular mechanism
and an explanation for tumor promotion,
suggesting that tumor promoters are
chemical and physical agents that can
activate signaling pathways that stimu-
late the activity of transcription factors
that regulate the expression of genes
involved in cell proliferation and neo-
plastic trasformation. This hypothesis
implicated that chronic elevation of c-
Jun’s expression or activity as brought
about by tumor promoters should lead to
oncogenic transformation. However,
direct genetic evidence in favor of this
hypothesis has been lacking. Unlike
other mammalian proto-oncogenes,
mutations in the c-jun locus have not
been found in human or murine cancers
and overexpression of the normal c-Jun
protein does not readily result in trans-
formation of rodent fibroblasts (Shaulian
and Karin, 2002). This important defi-
ciency has finally been rectified. Eferl et
al. report in the recent issue of Cell that
a targeted disruption of the c-jun gene in
mouse hepatocytes does not interfere
with normal function, but prevents the
emergence of hepatocellular carcino-
mas in response to a classical model of
tumor initiation-tumor promotion (Eferl
et al., 2003). These results not only
prove that c-Jun is a critical component
of the carcinogenic mechanism but also
suggest that c-Jun antagonists may be
used in chemoprevention of liver cancer,
a significant health problem in certain
parts of the world.
The acute or chronic loss of hepatic
function caused by alcohol, viral infection,
or other hepatotoxic drugs can result in
severe illness such as fulminant hepatitis,
or cirrhosis, and greatly increases the risk
for eventual development of hepatocellu-
lar carcinoma (Okuda, 2000). Chronic
infections with the hepatitis B virus (HBV)
and the hepatitis C virus (HCV) represent
major risk factors for hepatocellular carci-
noma (Okuda, 2000). AP-1 was reported
to be activated in both hepatocellular car-
cinoma and chronic hepatitis (Liu et al.,
2002). In vitro studies using liver-derived
cell lines have demonstrated rapid activa-
tion of AP-1 by HBV or HCV proteins
(Kato et al., 2000). Thus, there had been
ample reasons to suspect the involve-
ment of c-Jun or other AP-1 proteins in
liver cancer.
In addition to c-Jun and c-Fos, AP-1
transcription factors are composed of
homo- and heterodimers of basic region-
leucine zipper (bZIP) proteins that belong
to the Jun (c-Jun, JunB, and JunD) and
Fos (c-Fos, FosB, Fra-1, and Fra-2) sub-
families, all of which recognize the AP-1
Oncogene at last—c-Jun promotes liver cancer in mice
c-Jun, a component of transcription factor AP-1, has been known to play an important role in the control of cell prolifera-
tion. It was also suspected to be a critical mediator of tumor promotion. In a recent paper in Cell, Eferl et al. have now pro-
vided conclusive evidence that c-Jun expression is critical for induction of liver cancer by a classical protocol of tumor
initiation—tumor promotion.
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binding site or TPA response element
(TRE) in the regulatory region of AP-1
target genes (Angel and Karin, 1991;
Shaulian and Karin, 2002). These pro-
teins also can heterodimerize with other
transcription factors such as members of
the ATF/CREB and Maf/Nrl subfamilies
(Shaulian and Karin, 2002). In addition to
phorbol ester tumor promoters, such as
TPA, AP-1 transcription factors are acti-
vated by many physiological and patho-
physiological stimuli including growth
factors, oncoproteins such as Src and
Ras, proinflammatory cytokines, and UV
radiation (Angel and Karin, 1991). Many
of these stimuli can function as tumor
promoters or are known to activate onco-
genic signaling cascades. Amongst the
AP-1 proteins, c-Jun seems to be most
important for stimulation of cell prolifera-
tion (Shaulian and Karin, 2002). Mouse
fibroblasts lacking c-Jun exhibit a severe
proliferation defect mostly due to a dra-
matic extension of their G1 transition time
(Schreiber et al., 1999).When exposed to
UV radiation, these cells do not undergo
apoptosis but exhibit premature senes-
cence and reduced ability to re-enter the
cell cycle (Shaulian et al., 2000).
Fibroblasts deficient in other Jun or Fos
proteins do not exhibit such defects, and
there is even evidence that JunD may be
a negative regulator of cell proliferation
(Shaulian and Karin, 2002). Interestingly,
the defective proliferation of c-Jun-defi-
cient cells has been attributed to elevated
expression of p53 and its target gene
p21waf1 (Schreiber et al., 1999; Shaulian
et al., 2000). Although overexpression of
c-Jun is usually not sufficient for transfor-
mation of rodent fibroblasts, when coex-
pressed with the oncogenic Ha-Ras
(V12) protein, c-Jun does augment Ras-
mediated cell transformation (Binétruy et
al., 1991). This activity is not exhibited by
JunB or JunD and is dependent on the N-
terminal phosphorylation of c-Jun by Jun
kinases (JNKs) (Smeal et al., 1991).
Furthermore, mouse fibroblasts lacking
c-Jun are refractory to transformation by
oncogenes, such as Ha-ras or v-src
(Johnson et al., 1996). Thus, there has
been considerable evidence that in cul-
tured fibroblasts, c-Jun is required for
proper cell proliferation and for oncogenic
transformation. However, the evidence for
c-Jun’s involvement in tumor formation in
vivo has been lacking, until now.
c-Jun-deficient mice die between
embryonic days E12.5 and E13.5 from
massive apoptosis of hepatoblasts, ery-
throblasts, and other cell types (Hilberg
et al., 1993; Johnson et al., 1993). To
overcome this problem, mice harboring a
“floxed” c-jun allele that can be deleted in
designated cell types upon expression of
the Cre recombinase have been devel-
oped. Using this system, the Wagner lab
has found that c-Jun expression is
required for proper proliferation in post-
natal hepatocytes (Behrens et al., 2002).
Moreover, the deletion of c-jun in hepato-
cytes does compromise the ability of
these cells to enter the cell cycle and
undergo rapid proliferation after partial
hepatectomy (Behrens et al., 2002).
Using mice lacking c-Jun in hepato-
cytes (so called c-jun∆li mice), Eferl et al.
have examined the role of c-Jun in liver
carcinogenesis (Eferl et al., 2003). They
employed a well-established model of
chemical carcinogenesis based on the
tumor initiator diethylnitrosamine (DEN)
and the tumor promoter phenobarbital
(Kato et al., 1993). The results were
clear-cut; liver tumor mass was dramati-
cally reduced and survival rate was
notably improved in c-jun∆li mice in com-
parison to the “floxed” mice (c-junF/F)
used as controls. Eferl et al. investigated
the mechanism accounting for the
reduced tumorigenic effect and found
that apoptosis was increased in liver
tumor cells originating from c-jun∆li mice,
whereas the proliferation of these cells
was not reduced in comparison to tumor
cells derived from c-junF/F mice. These
results seem unexpected since earlier
work from the same group has shown
that c-Jun is required for optimal hepato-
cyte proliferation (Behrens et al., 2002).
Most likely, those tumors that form in c-
jun∆li mice have found ways to achieve
high rates of cell proliferation even in c-
Jun’s absence. Eferl et al. used inducible
Cre expression to determine at which
stage of liver tumor development c-Jun
was required. The results suggested to
them that c-Jun is required in the initia-
tion stage of liver carcinogenesis but not
during progression. However, the partic-
ular experimental design used did not
allow clear-cut evaluation of whether c-
Jun is involved in tumor promotion.
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Figure 1. Putative scenario of c-Jun function in tumor development
When normal liver cells are exposed to a tumor initiator (carcinogen), both c-Jun and p53 are induced and c-Jun can antagonize the pro-apo-
ptotic and anti-proliferative activities of p53 (initiation stage). Once cells are transformed, they may become insensitive to the anti-proliferative
activity of p53 (early cancer stage). In advanced stages of cancer, most of the tumor cells have incurred p53 gene mutations rendering p53 non-
functional, so c-Jun cannot affect p53 function at this stage.
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Based on a protocol in which tumors
were induced by administration of DEN
alone in the absence of phenobarbital,
Eferl et al. conclude that c-Jun is
required for initiation and not promotion.
Yet, in another experiment, they deleted
c-Jun after tumor initiation and found
reduced tumor incidence. Most likely, c-
Jun is required for the survival of initiated
cells and thus is needed for tumor pro-
moter action, whose major function is the
increased survival and expansion of initi-
ated cells. As the role of c-Jun in DNA
repair or the effect of its deletion on for-
mation of mutagenic lesions in response
to DEN has not been evaluated, it is diffi-
cult to conclude that c-Jun is required for
tumor initiation per se.
How can c-Jun prevent apoptosis?
Eferl et al. analyzed the anti-apoptotic
function of c-Jun using a cell culture sys-
tem and found that c-Jun-deficient
hepatocytes are more sensitive to TNFα-
induced apoptosis and that this sensiti-
zation was rescued by a p53 deficiency.
They also found that a p53-regulated
pro-apoptotic gene, Noxa, was upregu-
lated in c-Jun-deficient tumors. These
results suggest that p53 may be required
for TNFα-induced apoptosis. However,
until now, TNFα-induced apoptosis has
never been shown to depend on p53
activation and TNFα was not known 
as a p53 activator. Yet, the connection
between c-Jun and p53, as described
above, is certainly not surprising. c-Jun-
deficient fibroblasts exhibit elevated
expression of p53 and its target gene
p21waf1, which encodes an inhibitor of
cyclin-dependent kinases (Schreiber et
al., 1999). Indeed, the elevated expres-
sion of p53 and p21waf1 was shown to be
the major cause of the proliferation
defect of these cells. Elevated p53 and
p21waf1 expression are also responsible
for the extended UV-induced growth
arrest in c-jun−/− fibroblasts (Shaulian et
al., 2000).Thus the important question is
how c-Jun controls p53 expression and
transcriptional activity. Although this
mechanism remains a mystery, Eferl et
al. show that c-Jun-deficient liver tumors
accumulate high levels of p53 protein,
just like c-Jun-deficient fibroblasts.
Curiously, however, elevated levels of
p53 could not be detected in c-Jun-defi-
cient hepatocytes.
Apoptosis is a physiological mecha-
nism that eliminates undesired cells dur-
ing development, immune responses,
and oncogenic transformation. c-Jun
appears to be both a positive and a neg-
ative regulator of apoptosis (Shaulian
and Karin, 2002).The exact function of c-
Jun is likely to be cell type and stimulus
specific. For example, inhibition of c-Jun
activity protects sympathetic neurons
against NGF withdrawal-induced apop-
tosis (Ham et al., 1995). Mice expressing
a c-Jun with alanines at positions 63 and
73 (c-JunA63/73), which can no longer
be phosphorylated by JNK, are resistant
to kainate-mediated neuronal apoptosis
(Behrens et al., 1999). In contrast to
these results, the liver of c-jun−/− fetal
mice exhibits elevated numbers of apo-
ptotic cells, suggesting that c-Jun has an
anti-apoptotic function (Eferl et al.,
1999). This anti-apoptotic activity does
not seem to depend on JNK-mediated
phosphorylation, as mice expressing c-
Jun (A63/73) are fully susceptible to liver
carcinogenesis (Eferl et al., 2003).
Rather, the anti-apoptotic function of c-
Jun may be related to its ability to reduce
p53 accumulation (Schreiber et al.,
1999) and inhibit p53 binding to the
p21waf1 promoter (Shaulian et al., 2000).
Thus, the intriguing antagonism between
c-Jun and p53, a major tumor suppres-
sor, may underlie the tumor-promoting
activity of c-Jun (Figure 1). When normal
liver cells are exposed to a tumor initiator
like DEN, which is a potent genotoxic
agent, both c-Jun and p53 are induced
and c-Jun can antagonize the pro-apo-
ptotic and anti-proliferative activities of
p53 (Figure 1). Thus, c-Jun-deficient
cells would be eliminated more readily
than wild-type cells through p53-mediat-
ed apoptosis. This accounts for reduced
tumor incidence in the absence of c-Jun.
However, once wild-type or c-jun−/− cells
are transformed, they may become
insensitive to the anti-proliferative activi-
ty of p53 (Figure 1). In advanced stages
of cancer, most of the tumor cells have
incurred p53 gene mutations rendering
p53 nonfunctional, so c-Jun cannot
affect p53 function at this stage. Based
on this scheme, c-Jun inhibitors may be
particularly useful during pre-cancerous
states like cirrhosis or chronic viral infec-
tion, as chemopreventive agents, but
rather useless in the therapy of
advanced p53-mutated tumors (Figure
1). The design of c-Jun inhibitors should
be therefore seriously considered and
contemplated. The availability of such
inhibitors may further clarify how c-Jun
acts to promote liver cancer and possibly
other forms of cancer as well.
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